Common Contracts
3 similar Joint Filing Agreement contracts by Orbimed Advisors LLC
EXHIBIT A JOINT FILING AGREEMENTJoint Filing Agreement • February 12th, 2021 • Orbimed Advisors LLC • Pharmaceutical preparations
The undersigned hereby agree that the Statement on this Schedule 13G dated February 12, 2021 (the “Schedule 13G”), with respect to the Common Stock, par value $0.0001 per share, of Theravance Biopharma, Inc. is filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, and that this Agreement shall be included as an Exhibit to this Schedule 13G. Each of the undersigned agrees to be responsible for the timely filing of the Schedule 13G, and for the completeness and accuracy of the information concerning itself contained therein. This Agreement may be executed in any number of counterparts, all of which taken together shall constitute one and the same instrument.
EXHIBIT A JOINT FILING AGREEMENTJoint Filing Agreement • February 12th, 2021 • Orbimed Advisors LLC • Pharmaceutical preparations
The undersigned hereby agree that the Statement on this Schedule 13G dated February 12, 2021 (the “Schedule 13G”), with respect to the Common Stock, par value $0.0001 per share, of Strongbridge Biopharma plc is filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, and that this Agreement shall be included as an Exhibit to this Schedule 13G. Each of the undersigned agrees to be responsible for the timely filing of the Schedule 13G, and for the completeness and accuracy of the information concerning itself contained therein. This Agreement may be executed in any number of counterparts, all of which taken together shall constitute one and the same instrument.
EXHIBIT A JOINT FILING AGREEMENTJoint Filing Agreement • February 12th, 2021 • Orbimed Advisors LLC • Biological products, (no disgnostic substances)
The undersigned hereby agree that the Statement on this Schedule 13G dated February 12, 2021 (the “Schedule 13G”), with respect to the Common Stock, par value $0.0001 per share, of Adverum Biotechnologies, Inc. is filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, and that this Agreement shall be included as an Exhibit to this Schedule 13G. Each of the undersigned agrees to be responsible for the timely filing of the Schedule 13G, and for the completeness and accuracy of the information concerning itself contained therein. This Agreement may be executed in any number of counterparts, all of which taken together shall constitute one and the same instrument.
